STOCK TITAN

Merit Medical's Brian G. Lloyd sells 16,722 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Merit Medical Systems (MMSI) Chief Legal Officer and Secretary Brian G. Lloyd exercised options for 16,722 shares on November 16, 2026, at an exercise price of $37.71 per share, then sold 16,722 shares at a weighted-average $86.325 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted May 21, 2026.

Insider Lloyd Brian G.
Role CHIEF LEGAL OFFICER, SECRETARY
Sold 16,722 shs ($1.44M)
Approx. gross sale proceeds $1.44M
Approx. exercise cost $631K
Share of Position Sold 21.8%
Type Security Shares Price Value
Exercise Non-qualified stock options (right to buy) F1, F3 16,722 $0.00 $0.00
Exercise Common Stock, No Par Value F1 16,722 $37.71 $631K
Sale Common Stock, No Par Value F1, F2 16,722 $86.325 $1.44M
Holding Non-qualified stock options (right to buy) F4 -- -- --
Holding Non-qualified stock options (right to buy) F5 -- -- --
Holding Non-qualified stock options (right to buy) F6 -- -- --
Holding Common Stock, No Par Value -- -- --
Holdings After Transaction: Non-qualified stock options (right to buy) — 31,351 options (Direct); Common Stock, No Par Value — 60,132 shares (Direct); Common Stock, No Par Value — 2,000 shares (Indirect, By 401(k) plan)
Holdings Before and After: Non-qualified stock options (right to buy), 48,073 to 31,351 options (Direct); Common Stock, No Par Value, 60,132 to 60,132 shares (Direct)
Footnotes (6)
  1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2026.
  2. F2. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.88 to $86.90, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. F3. Become exercisable in equal annual installments of 25% commencing on 02/26/2021.
  4. F4. Become exercisable in equal annual installments of 25% commencing on 03/19/2022.
  5. F5. Becomes exercisable in equal annual installments of 25% commencing 02/28/2023.
  6. F6. Become exercisable in equal annual installments of 25% commencing on 02/28/2024.
Shares acquired through option exercise 16,722 shares November 16, 2026
Exercise price $37.71 per share Options exercised November 16, 2026
Shares sold 16,722 shares November 16, 2026
Weighted-average sale price $86.325 per share Multiple transactions on November 16, 2026
Lowest sale price $85.88 per share Range of prices for the November 16, 2026 sales
Highest sale price $86.90 per share Range of prices for the November 16, 2026 sales
Rule 10b5-1 trading plan regulatory
"the exercise and sale reported for November 16, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"the sale of 16,722 shares reported for November 16, 2026"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Non-qualified stock options (right to buy) financial
"the direct option positions expiring March 19, 2028"
exercise price financial
"the options exercised on November 16, 2026"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MMSI shares did Brian G. Lloyd sell, and at what prices?

Brian G. Lloyd sold 16,722 shares on November 16, 2026, at a weighted-average $86.325 per share. The shares were sold in multiple transactions at prices ranging from $85.88 to $86.90 per share under a Rule 10b5-1 trading plan adopted May 21, 2026.

What direct MMSI option positions were listed for Brian G. Lloyd?

The listed direct options covered 9,681 underlying shares at a $56.25 exercise price, expiring March 19, 2028; 8,094 underlying shares at $65.03, expiring February 28, 2029; and 13,576 underlying shares at $70.58, expiring February 28, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lloyd Brian G.

(Last)(First)(Middle)
1600 WEST MERIT PARKWAY

(Street)
SOUTH JORDAN UTAH 84095

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MERIT MEDICAL SYSTEMS INC [ MMSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF LEGAL OFFICER, SECRETARY
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, No Par Value2,000IBy 401(k) plan
Common Stock, No Par Value11/16/2026M(1)16,722A$37.7176,854D
Common Stock, No Par Value11/16/2026S(1)16,722D$86.325(2)60,132D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified stock options (right to buy)$37.7111/16/2026M(1)16,72202/26/2021(3)02/26/2027Common Stock16,722$00D
Non-qualified stock options (right to buy)$56.2503/19/2022(4)03/19/2028Common Stock9,6819,681D
Non-qualified stock options (right to buy)$65.0302/28/2023(5)02/28/2029Common Stock8,0948,094D
Non-qualified stock options (right to buy)$70.5802/28/2024(6)02/28/2030Common Stock13,57613,576D
Explanation of Responses:
1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2026.
2. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.88 to $86.90, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. Become exercisable in equal annual installments of 25% commencing on 02/26/2021.
4. Become exercisable in equal annual installments of 25% commencing on 03/19/2022.
5. Becomes exercisable in equal annual installments of 25% commencing 02/28/2023.
6. Become exercisable in equal annual installments of 25% commencing on 02/28/2024.
/s/ Brian G. Lloyd11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading